If we play with your narrative that it's about saving face one...

If we play with your narrative that it's about saving face one way they can do so is recognising that what they said was primarily about potency assays and manufacturing controls with efficacy not being in question after ODAC.

The suggestion was to address this via another trial. It was not a requirement as was clarified at the follow up type C meeting after the CRL.

Fortunately MSB, in constant dialogue with the FDA, believes they have done exactly what was asked without a trial.

Considering you've dropped the potency assay argument it seems you believe so too.

"... only in my opinion." yes, yes - that is your regular go-to statement when bordering absurdity. In contrast my comment is not my opinion as it is verifiable in the announcements.